NT$ 17
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
LAUNXP Biomedical Co. Ltd. specializes in developing innovative pharmaceutical treatments for various types of cancer. Their product line includes therapies designed to combat tumor growth and inhibit cell proliferation, notably utilizing advanced platforms such as virus-like nanoparticles and other nanoparticle-based drug delivery systems. The company was established on September 24, 2015, and its primary corporate operations are based in Taichung, Taiwan.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only